FDA's Gastrointestinal Drugs Advisory Committee will meet April 12 to discuss the safety of cisapride and methods to reduce the occurrence of adverse events related to the product. The meeting begins at 8:15 a.m. at the Hilton in Gaithersburg, Md
You may also be interested in...
Janssen will detail professional education campaign plans for conveying cardiac risks associated with the nighttime heartburn treatment Propulsid (cisapride) at the April 12 FDA advisory committee review of the product's safety.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011